Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Direct materials for restoring caries lesions: Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs.
Pilcher L, Pahlke S, Urquhart O, O'Brien KK, Dhar V, Fontana M, González-Cabezas C, Keels MA, Mascarenhas AK, Nascimento MM, Platt JA, Sabino GJ, Slayton RL, Tinanoff N, Young DA, Zero DT, Tampi MP, Purnell D, Salazar J, Megremis S, Bienek D, Carrasco-Labra A. Pilcher L, et al. Among authors: purnell d. J Am Dent Assoc. 2023 Feb;154(2):e1-e98. doi: 10.1016/j.adaj.2022.09.012. Epub 2023 Jan 5. J Am Dent Assoc. 2023. PMID: 36610925 Review.
The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.
Katayama A, Starczynski J, Toss MS, Shaaban AM, Provenzano E, Quinn CM, Callagy G, Purdie CA, Millican-Slater R, Purnell D, Chagla L, Oyama T, Pinder SE, Chan S, Ellis I, Lee AHS, Rakha EA. Katayama A, et al. Among authors: purnell d. Histopathology. 2022 Oct;81(4):511-519. doi: 10.1111/his.14728. Epub 2022 Aug 8. Histopathology. 2022. PMID: 35879836 Free PMC article.
Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.
Rakha EA, Miligy IM, Quinn CM, Provenzano E, Shaaban AM, Marchiò C, Toss MS, Gallagy G, Murray C, Walshe J, Katayama A, Eldib K, Badr N, Tanchel B, Millican-Slater R, Purdie C, Purnell D, Pinder SE, Ellis IO, Lee AHS. Rakha EA, et al. Among authors: purnell d. Br J Cancer. 2021 May;124(11):1836-1842. doi: 10.1038/s41416-021-01351-8. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762723 Free PMC article.
Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
Katayama A, Miligy IM, Shiino S, Toss MS, Eldib K, Kurozumi S, Quinn CM, Badr N, Murray C, Provenzano E, Callagy G, Martyn C, Millican-Slater R, Purdie C, Purnell D, Pinder SE, Oyama T, Shaaban AM, Ellis I, Lee AHS, Rakha EA. Katayama A, et al. Among authors: purnell d. Mod Pathol. 2021 Jul;34(7):1271-1281. doi: 10.1038/s41379-021-00738-5. Epub 2021 Feb 1. Mod Pathol. 2021. PMID: 33526875 Free PMC article.
Baseline Characteristics of the 2015-2019 First Year Student Cohorts of the NIH Building Infrastructure Leading to Diversity (BUILD) Program.
Norris KC, McCreath HE, Hueffer K, Aley SB, Chavira G, Christie CA, Crespi CM, Crespo C, D'Amour G, Eagan K, Echegoyen LE, Feig A, Foroozesh M, Guerrero LR, Johanson K, Kamangar F, Kingsford L, LaCourse W, Maccalla NM, Márquez-Magaña L, Mathur A, Maton K, Mehravaran S, Morales DX, Nakazono T, Ofili E, Okuyemi K, Ott L, Parangan-Smith A, Pfund C, Purnell D, Reynolds A, Rous PJ, Saetermoe C, Snyder K, Vishwanatha JK, Wagler A, Wallace SP, Seeman T. Norris KC, et al. Among authors: purnell d. Ethn Dis. 2020 Sep 24;30(4):681-692. doi: 10.18865/ed.30.4.681. eCollection 2020 Fall. Ethn Dis. 2020. PMID: 32989368 Free PMC article.
111 results